Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Sigma-Aldrich has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology throughout its global operations.
Subscribe to our email newsletter
Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia. Financial details of the deal were not disclosed.
According to Sigma-Aldrich, the use of ddRNAi to develop therapeutics is recognized as having a number of critical advantages available over alternative RNAi and other gene silencing technologies. These include the wide range of technologies to deliver the ddRNAi molecules into the target cell and the ability to control the expression and timing of gene silencing, particularly important to the development of drugs for the pharmaceutical industry.